Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55.98 USD | -0.76% | +0.59% | -10.72% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.72% | 4.79B | |
+3.30% | 43.43B | |
+47.81% | 41.69B | |
+8.15% | 41.31B | |
-10.92% | 27.14B | |
+8.30% | 25.28B | |
-24.57% | 18.47B | |
+29.09% | 12.59B | |
+1.03% | 12.33B | |
+8.80% | 11.03B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- CRISPR Therapeutics, ViaCyte Secure Health Canada's Approval for Clinical Trial of Diabetes Drug Candidate